No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected fibromyalgia syndrome.

Autor: van Vliet J; Department of Neurology, Canisius Wilhelmina Hospital Nijmegen, P.O. Box 9015, 6500 GS Nijmegen, The Netherlands; Neuromuscular Centre Nijmegen, Department of Neurology, Radboud University Medical Centre, Huispost 935, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: judithvanvliet@hotmail.com., Verrips A; Department of Neurology, Canisius Wilhelmina Hospital Nijmegen, P.O. Box 9015, 6500 GS Nijmegen, The Netherlands., Tieleman AA; Neuromuscular Centre Nijmegen, Department of Neurology, Radboud University Medical Centre, Huispost 935, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands., Scheffer H; Department of Human Genetics, Radboud University Medical Centre, Huispost 836, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands., Cats HA; Department of Rheumatology, Sint Maartenskliniek, P.O. Box 9011, 6500 GM Nijmegen, The Netherlands., den Broeder AA; Department of Rheumatology, Sint Maartenskliniek, P.O. Box 9011, 6500 GM Nijmegen, The Netherlands., van Engelen BG; Neuromuscular Centre Nijmegen, Department of Neurology, Radboud University Medical Centre, Huispost 935, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Jazyk: angličtina
Zdroj: Neuromuscular disorders : NMD [Neuromuscul Disord] 2016 Jun; Vol. 26 (6), pp. 370-3. Date of Electronic Publication: 2016 Apr 06.
DOI: 10.1016/j.nmd.2016.03.009
Abstrakt: Myotonic dystrophy type 2 (DM2) is a rare, autosomal dominant, multisystem disorder with proximal weakness, myotonia, pain and cataract as important symptoms. Given the assumed underreporting of DM2 in the Netherlands combined with the predominant role of pain in DM2 as well as in fibromyalgia syndrome (FMS), we hypothesized there will be an excess prevalence of DM2 in patients with (suspected) FMS. Our objective was to determine the prevalence of DM2 in patients with suspected FMS. A prevalence of 2% was considered a relevant excess frequency. Between November 2011 and April 2014, 398 patients with suspected FMS who had been assessed by a rheumatologist participated in this cross-sectional study. 95% of the study population was female, with a mean age of 42 years. The final ICD-9 diagnoses were collected, in 96% the diagnosis was FMS. 92% met the 2010 American College of Rheumatology (ACR) diagnostic criteria for FMS. A questionnaire including neuromuscular symptoms was completed. Creatine kinase was determined, and genetic testing for DM2 was conducted in all patients. DM2 was established in only one patient (0.25%, 95% CI 0.04-1.4%), thus disapproving our hypothesis of a relevant prevalence of 2%. Our results suggest that patients with suspected FMS should not routinely be tested for DM2.
(Copyright © 2016 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: